Company to Host Conference Call at 8:30am ETREHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine months ended September 30, 2025, prior to the open of the U.S. financial markets on Mo ...

REHOVOT, Israel and Hoboken, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate in the Stifel 2025 Healthcare Conference, to be held to be held at the Lotte New York Palace Hotel, New-York, NY on November 11–13, 2025. Mr. London is sched ...

Core Insights - Kamada Ltd. has received FDA approval for its plasma collection center in Houston, Texas, allowing it to commence commercial sales of normal source plasma [1][2][3] - The Houston facility is expected to have an annual collection capacity of approximately 50,000 liters of plasma and generate estimated annual revenues of $8 million to $10 million at full capacity [2][6] - The company plans to seek approval from the European Medicines Agency (EMA) for the Houston center following the FDA approval [3][7] Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, with a portfolio that includes six FDA-approved specialty plasma-derived products [4] - The company's growth strategy includes organic growth from commercial activities, new business development, expansion of plasma collection operations, and advancing product candidates through R&D [4] - Kamada currently operates three plasma collection centers in Texas: Houston, San Antonio, and Beaumont, which collectively enhance its capacity for specialty and normal source plasma collection [3][4]

Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, specializing in specialty plasma-derived therapies [3] - The company has a portfolio of six FDA-approved specialty plasma-derived products, including KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG®, and HEPAGAM B® [3] - FIMI Opportunity Funds is the controlling shareholder, owning approximately 38% of the outstanding ordinary shares [3] Financial Results Announcement - Kamada will release its financial results for the second quarter and first half ended June 30, 2025, prior to the U.S. market opening on August 13, 2025 [1] - An investment community conference call will be held on August 13 at 8:30am ET to discuss the results and answer questions [2] Growth Strategy - The company aims for organic growth through commercialization and life cycle management of its proprietary products [3] - Kamada is pursuing new business development opportunities, including in-licensing, collaboration, and mergers and acquisitions to enhance its product portfolio [3] - The company is expanding plasma collection operations to support revenue growth and increasing demand for hyper-immune plasma [3] - Kamada is advancing the development of additional product candidates, with a focus on unmet medical needs, including the InnovAATe clinical trial for Inhaled AAT [3]

Core Viewpoint - Kamada Ltd. continues its operations and manufacturing in Israel despite evolving circumstances in the Middle East, ensuring that the global availability of its products remains uninterrupted [1][2]. Company Overview - Kamada Ltd. is a global biopharmaceutical company specializing in products for rare and serious conditions, particularly in the specialty plasma-derived therapies field [3]. - The company has a portfolio of six FDA-approved specialty plasma-derived products, including KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG®, and HEPAGAM B®, along with other proprietary products and biosimilars [3]. - FIMI Opportunity Funds is the controlling shareholder, owning approximately 38% of the outstanding ordinary shares [3]. Business Continuity and Operations - The company is focused on business continuity and has sufficient product levels available through distribution centers outside Israel, despite temporary disruptions due to the closing of Israeli airspace [2][4]. - Kamada is actively monitoring the situation and prioritizing the well-being of its employees while ensuring that client demands are met without shortages [2][4]. Growth Strategy - Kamada's growth strategy is built on four pillars: organic growth through commercialization, securing new business development opportunities, expanding plasma collection operations, and advancing product candidates in development [3]. - The company operates three plasma collection centers in the United States to support revenue growth and meet increasing demand for hyper-immune plasma [3]. - The lead product candidate is Inhaled AAT, currently progressing through the InnovAATe clinical trial, a pivotal Phase 3 trial [3].

Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, specializing in specialty plasma-derived therapies [3] - The company has a portfolio of six FDA-approved specialty plasma-derived products, including KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG®, and HEPAGAM B® [3] - FIMI Opportunity Funds is the controlling shareholder, owning approximately 38% of the outstanding ordinary shares [3] Financial Results Announcement - Kamada will release its financial results for the first quarter ending March 31, 2025, prior to the opening of U.S. financial markets on May 14, 2025 [1] - An investment community conference call will be held on the same day at 8:30am ET to discuss the results and answer questions [2] Growth Strategy - The company aims for organic growth through commercialization and life cycle management of its proprietary products [3] - Kamada is pursuing new business development opportunities, including in-licensing, collaboration, and M&A to enhance its product portfolio [3] - The company is expanding plasma collection operations to support revenue growth and meet increasing demand for hyper-immune plasma [3] - Kamada is advancing the development of additional product candidates, with a focus on unmet medical needs, including the InnovAATe clinical trial for Inhaled AAT [3]